5-(3-Oxo-2,3,4,5-tetrahydropyridazin-6-yl)indolin-2-one | 70386-01-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-(3-Oxo-2,3,4,5-tetrahydropyridazin-6-yl)indolin-2-one
• 英文别名: 1,3-dihydro-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H-indol-2-one；5-(6-oxo-4,5-dihydro-1H-pyridazin-3-yl)-1,3-dihydroindol-2-one
• CAS: 70386-01-5
• 化学式: C₁₂H₁₁N₃O₂
• 分子量: 229.238
• InChiKey: WXQSPVFHVLTAFJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  70.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-(2-oxo-1H-indol-5-yl)-4-oxobutanoic acid 在 一水合肼 作用下， 以 乙醇 为溶剂， 生成 5-(3-Oxo-2,3,4,5-tetrahydropyridazin-6-yl)indolin-2-one
  参考文献：
  名称：

  Dihydropyridazinone cardiotonics. The discovery and inotropic activity of 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H-indol-2-one

  摘要：

  We discovered that 6 (N-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide) is a potent positive inotrope in dogs, and we have prepared several lactam analogues of this agent. These included 16 (1,3-dihydro-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H-indol-2-one), 32 (the analogous quinolin-2-one), and 37 (the analogous benzazepin-2-one). The inotropic ED50's of these compounds were 24, 3.3, and 5.2 micrograms/kg, respectively, after iv administration to pentobarbital-anesthetized dogs. Compound 20 (LY195115, 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H-i ndol-2- one), the geminal dimethyl analogue of 16, was 3.5-fold more potent than 16 when administered iv (ED50 = 6.8 micrograms/kg). However, the most profound effect of the geminal alkyl substitution was on oral activity. The approximate ED50's of 20 and 16 after oral administration to conscious dogs were 25 and 400 micrograms/kg, respectively. The increase in contractility produced by 25 micrograms/kg of 20 was maximally sustained in excess of 8 h. Thus, 20 is one of the most potent and long-acting oral inotropes described to date.

  DOI：

  10.1021/jm00160a006

文献信息

• SUSPENSION FORMULATIONS
  申请人：VECTURA LIMITED

  公开号：US20130142879A1

  公开（公告）日：2013-06-06

  The present invention relates to suspension formulations, especially those for delivering a pharmaceutically active agent in aerosol form using a spray or aerosol device, such as a pressurised metered dose inhaler (pMDI). The formulations may be for pulmonary, nasal, buccal or topical administration, but are preferably for pulmonary inhalation.

  本发明涉及悬浮制剂，特别是用喷雾器或气雾剂装置（如压力计量剂量吸入器（pMDI））以气雾形式输送药物活性剂的制剂。这些制剂可用于肺部、鼻部、口腔或局部给药，但最好用于肺部吸入。
• Neue 2-Aryl-3,4-diaza-bicyclo(4.n.0)alken-(2)-one-(5), Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
  申请人：BASF Aktiengesellschaft

  公开号：EP0068310A1

  公开（公告）日：1983-01-05

  Die vorliegende Erfindung betrifft 2-Aryl-3,4-diaza-bicyclo[4.n.O]alken-(2)-one-(5) der Formel worin m und n gleich oder verschieden sind und die Zahlen 1, 2 oder 3 bedeuten, und R, R1, R2 und R3 gleich oder verschieden sind und Wasserstoffatome oder Alkylgruppen mit 1 bis 6 C-Atomen bedeuten, sowie deren Herstellung. Die neuen Verbindungen eignen sich zur Behandlung von Bluthochdruck und thrombo-embolischen Erkrankungen.

  本发明涉及式 2-芳基-3,4-二氮杂双环[4.n.O]烯-(2)-酮-(5) 其中 m 和 n 相同或不同，且为数字 1、2 或 3，以及 R、R1、R2 和 R3 相同或不同，表示氢原子或具有 1 至 6 个碳原子的烷基，以及它们的制备方法。 新化合物适用于治疗高血压和血栓栓塞性疾病。
• Pyridazone inotropic agents
  申请人：ELI LILLY AND COMPANY

  公开号：EP0155798A1

  公开（公告）日：1985-09-25

  This invention provides for the use of certain pyridazi- nones as positive inotropic agents.

  本发明提供了某些哒嗪酮类药物作为正性肌力药物的用途。
• Indoline and 2-indolinone derivatives
  申请人：ELI LILLY AND COMPANY

  公开号：EP0161918A2

  公开（公告）日：1985-11-21

  This invention provides certain pyridazinone derivatives, their pharmaceutical formulations, and their use as positive inotropic agents.

  本发明提供了某些哒嗪酮衍生物、它们的药物制剂以及它们作为正性肌力药物的用途。
• Inhaler
  申请人：Vectura Delivery Devices Limited

  公开号：EP2082767A1

  公开（公告）日：2009-07-29

  An inhaler (1) is disclosed. It comprises a housing (2) to receive a strip (3) having a surface (3a) and a plurality of blister pockets (5) depending from said surface. Each blister pocket contains a dose of medicament for inhalation by a user. The inhaler has a blister strip drive mechanism (7) including a blister strip drive member (27) shaped to contact the strip along a line defined by the crease (30) between a blister pocket and said surface, to drive said strip.

  本发明公开了一种吸入器（1）。它包括一个外壳（2），用于容纳一个具有表面（3a）的条状物（3）和多个与所述表面相连的水泡袋（5）。每个水泡袋中装有一定剂量的药物，供使用者吸入。吸入器有一个泡罩条驱动机构（7），包括一个泡罩条驱动部件（27），其形状是沿着泡罩袋和所述表面之间的折痕（30）所确定的线接触泡罩条，以驱动所述泡罩条。